EMPLOYMENT AGREEMENTEmployment Agreement • December 18th, 2018 • Neuralstem, Inc. • Biological products, (no disgnostic substances) • Maryland
Contract Type FiledDecember 18th, 2018 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made and entered into as of this 12th day of December 2018, by and between Neuralstem, Inc., a Delaware corporation (the “Company”), and Kenneth C. Carter (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 10th, 2016 • Inspyr Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 10th, 2016 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made and entered into as of this 8th day of August 2016, by and between Inspyr Therapeutics, Inc. (fka GenSpera, Inc.), a Delaware corporation (the “Company”), and Ronald L. Shazer, M.D. (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 5th, 2016 • Inspyr Therapeutics, Inc. • Pharmaceutical preparations • California
Contract Type FiledAugust 5th, 2016 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made and entered into as of this 2nd day of August 2016, by and between GenSpera, Inc., a Delaware corporation (the “Company”), and Christopher Lowe (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • February 19th, 2016 • Neuralstem, Inc. • Biological products, (no disgnostic substances) • Maryland
Contract Type FiledFebruary 19th, 2016 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made and entered into as of this [*]th day of February 2016, by and between Neuralstem, Inc., a Delaware corporation (the “Company”), and Richard Daly (the “Employee”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 11th, 2016 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations • Massachusetts
Contract Type FiledJanuary 11th, 2016 Company Industry JurisdictionThis Employment Agreement (this “Agreement”) is made and entered into as of this 7th day of January 2016, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Mary T. Szela (the “Employee”).